DOI QR코드

DOI QR Code

Ki-67 Immunostaining and its Correlation with Microvessel Density in Patients with Mutiple Myeloma

  • Himani, Bhankar (Department of Pathology, University College of Medical Sciences and Guru Teg Bahadur Hospital) ;
  • Meera, Sikka (Department of Pathology, University College of Medical Sciences and Guru Teg Bahadur Hospital) ;
  • Abhimanyu, Sharma (Department of Pathology, University College of Medical Sciences and Guru Teg Bahadur Hospital) ;
  • Usha, Rusia (Department of Pathology, University College of Medical Sciences and Guru Teg Bahadur Hospital)
  • Published : 2016.05.01

Abstract

Purpose: To compare Ki-67 index and microvessel density MVD) in multiple myeloma and non-myeloma patients and their correlation with each other and other prognostic markers. Materials and Methods: Forty patients were enrolled in this study between 2011-2013, 30 with multiple myelomas and 10 with non-malignant disease as controls. Proliferative activity was analyzed by Ki-67 and microvessel density (MVC) was assessed by CD34 and compared between two groups. In myeloma patients, correlation between Ki-67, MVD and other prognostic factors was assessed by Pearson correlation coefficient. Results: According to Durie Salmon staging criteria, 13 patients were of stage 1, 5 of stage II and 12 of stage III. Ki-67 expression showed a positive correlation with MVD (r=0.729, p<0.001) and was significantly higher (p<0.0001) in myeloma patients (range 35-80%, mean 60.1 %) as compared to controls (range 8-25%, mean 18.1%). $MVD/mm^2$ was also significantly (p<0.0001) higher in myeloma patients (range $62-237/mm^2$, mean $178.0/mm^2$) than controls (range $5.2-50/mm^2$, mean $18.3/mm^2$). Ki-67 and MVD, both increased progressively with increasing stage of myeloma. Ki-67 showed significant positive correlation with blood urea and lactate dehydrogenase and a significant negative correlation with serum albumin. MVD showed a significant positive correlation with blood urea, lactate dehydrogenase, serum creatinine, ${\beta}2$ microglobulin and skeletal lesions. Conclusions: Ki-67 and MVD are indicators of aggressiveness and poor prognosis having significant correlation with each other and other prognostic markers of multiple myeloma. Routine assessment of these markers may help to identify high risk patients, who may benefit from with more aggressive therapy.

Keywords

Multiple myeloma;microvessel density;Ki-67 index;prognostic markers;angiogenesis

References

  1. Ahn M J, Park C K, Choi J H, et al (2001). Clinical significance of microvessel density in multiple myeloma patients. J Korean Med Sci, 16, 45-50. https://doi.org/10.3346/jkms.2001.16.1.45
  2. Alexandrakis MG, Passam FH, Dambaki C, et al (2004). The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol, 57, 856-60. https://doi.org/10.1136/jcp.2003.013110
  3. Dispenzieri A, Lacy MQ, Greipp PR (2009). Multiple myeloma In 'Wintrobe's Clinical Hematology 12th ed' Eds. John P. Greer et al. Walnut street, Philadelphia. (pp 2372-80).
  4. Drach J, Gattringer C, Glassl H, Drach D Huber H (1992). The biological and clinical significance of Ki-67 growth fraction in multiple myeloma. Hematol Oncol, 10, 125-134. https://doi.org/10.1002/hon.2900100209
  5. Fernando RC, de Carvalho F, Mazzotti DR, Evangelista AF, Braga WM et al (2015). Multiple myeloma cell lines and primary tumors proteoma: protein biosynthesis and immune system as potential therapeutic targets. Genes Cancer, 6, 462-71.
  6. International Myeloma Working Group (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working group. Br J Hematol, 121, 749-57. https://doi.org/10.1046/j.1365-2141.2003.04355.x
  7. Kumar L, Vikram P, Kochupillai V (2006). Recent advances in the management of multiple myeloma. Natl Med J India, 19, 80-9.
  8. Kyle R, Gertz MA, Witzig T, et al (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 78, 21-33. https://doi.org/10.4065/78.1.21
  9. Lai R, Medeiros LJ, Wilson CS, et al (1998). Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Mod Pathol, 11, 642-7.
  10. Lee N, Lee H, Moon SY, et al (2015). Adverse prognostic impact of bone marrow microvessel density in multiple myeloma. Ann Lab Med, 35, 563-9. https://doi.org/10.3343/alm.2015.35.6.563
  11. Lokhorst H, Boom S, Terpstra W, et al (1988). Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67. Br J Haematol, 69, 477-81. https://doi.org/10.1111/j.1365-2141.1988.tb02402.x
  12. Mark TM, Forsberg P, Ouansafi I, et al (2014). The Ki67/CD138 ratio independently predicts overall survival in the upfront treatment of newly diagnosed multiple myeloma. Blood, 124, 2016-6.
  13. Markovic O, Marisavljevic D, Cemerikic V, et al (2005). Proliferative activity of myeloma cells determined by Ki-67 antibody: biological and clinical significance. Vojnosanit Pregl, 62, 33-8. https://doi.org/10.2298/VSP0501033M
  14. Medinger M, Passweg J (2014). Role of tumor angiogenesis in hematological malignancies. Swiss Med Wkly, 144.
  15. Pruneri G, Bertolini F, Soligo D, et al (1999). Angiogenesis in myelodysplastic syndromes. Br J Cancer, 81, 1398-401. https://doi.org/10.1038/sj.bjc.6693515
  16. Rajkumar SV, Leong T, Roche PC, et al (2000). Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res, 6, 3111-6.
  17. Rajkumar SV, Mesa RA, Fonseca R, et al (2002). Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res, 8, 2210-16.
  18. Richardson PG, Mark TM, Lacy MQ (2013). Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. Crit Rev Oncol Hematol, 88, 36-44. https://doi.org/10.1016/j.critrevonc.2013.02.001
  19. Sezer O, Niemoller K, Eucker J, et al (2000). Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol, 79, 574-7. https://doi.org/10.1007/s002770000236
  20. Sridevi HB, Rai S, Suresh PK, Somesh MS, Minal J (2015). Pancytopenia in multiple myeloma- an enigma: our experience from tertiary care hospital. J Clin Diagn Res, 9, 4-6.
  21. Tichy M, Ticha V, Scudla V, Svachova M, Zapletalova J (2010). Analysis of bone marrow angiogenesis in multiple myeloma. Cesk Patol, 46, 15-9.
  22. Vacca A, Ribatti D, Roncali L, et al (1994). Bone marrow angiogenesis and progression in multiple myeloma. Br J Hematol, 87, 503-8. https://doi.org/10.1111/j.1365-2141.1994.tb08304.x
  23. Xu JL, Lai R, Kinoshita T, Nakashima N, Nagasaka T (2002). Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol, 55, 530-4. https://doi.org/10.1136/jcp.55.7.530